While the ALK fusion kinase clearly drives disease, it is not known if and how additional variants (co-mutations) coexisting with the ALK translocation may impact on tumor biology and explain the observed heterogeneity in clinical presentation, morphologic features, and response to treatment. The gene discussed is ALK; the disease is neoplasm.